The paper identifies RUNX1 inhibition as a strategy to induce NOXA-dependent apoptosis in pancreatic cancer, showing it blocks tumor growth in vivo and in organoids.

bioRxiv · Oct 21, 2021Cancer Biology

Cell cycle corruption in a preleukemic ETV6-RUNX1 model exposes RUNX1 addiction as a therapeutic target in acute lymphoblastic leukemia

J. P. Wray, E. M. Deltcheva, C. Boiers, S. E. Richardson, J. B. Chhetri, S. Gagrica, Y. Guo, A. Illendula, J. H. Martens, H. H. Stunnenberg, J. H. Bushweller, R. Nimmo, T. Enver

This study shows that RUNX1 addiction is a therapeutic target in acute lymphoblastic leukemia, as inhibiting RUNX1 activity spares normal hematopoiesis and affects multiple genetic subtypes.

bioRxiv · Dec 22, 2020 · PreprintCancer Biology

RUNX1 mitotically bookmarks target genes that are important for the mammary epithelial-to-mesenchymal transition

J. T. Rose, E. Moskovitz, J. R. Boyd, J. A. Gordon, N. A. Bouffard, A. J. Fritz, A. Illendula, J. H. Bushweller, J. B. Lian, J. L. Stein, G. S. Stein, S. Zaidi

This study identifies RUNX1 as a mitotic bookmarking factor that maintains epithelial gene expression and prevents EMT in mammary cells.

bioRxiv · Mar 12, 2020 · PreprintCancer Biology

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation

N. Zhou, A. Gutierrez Uzquiza, X. Y. Zheng, D. Vogl, A. L. Garfall, L. Bernabei, A. Saraf, L. Florens, M. P. Washburn, A. Illendula, J. H. Bushweller, L. Busino

This study identifies RUNX1 and RUNX3 as proteins that protect IKZF1 and IKZF3 from lenalidomide-induced degradation, thereby reducing the effectiveness of lenalidomide in multiple myeloma.

bioRxiv · Sep 20, 2018Cancer Biology